概要

In April 2018, HKEx made new rules to broaden Hong Kong’s listing regime. As part of the reforms, HKEx added a new chapter 19C to establish a new secondary listing route for Greater China and international companies that wish to secondary list in Hong Kong.

The topic has become popular amid the pressure felt by some of the China concepts stock listed in elsewhere especially US. Depending on the location and time of the company listed on the foreign stock exchange, its revenue / profit, market capitalisation, nature of business, existence of Weighted Voting Rights (‘WVR’) and Variable Interest Entity (‘VIE’) structure, a company already listed elsewhere may have several options to list in Hong Kong. Case studies will be used to illustrate such options.

宗旨

By the end of this webinar, participants will be able to:

- know about various options to list in Hong Kong for companies already listed elsewhere
- know about the relationship among biotech companies, WVR companies, VIE companies, dual primary listing and secondary listing
- obtain a one-page chart showing the relationship among them

內容

1. Small and Medium Enterprise (GEM)
2. Sizable companies (Rule 8.05) (Main Board)
3. Pre-profit companies
i. Mineral companies (Chapter 18) (Main Board)
ii. Project companies (Rule 8.05B(2)) (Main Board)
iii. Biotech companies (Chapter 18A) (Main Board)
- Case studies

4. WVR companies
- Case studies

5. Delist from other exchange and list in Hong Kong
- Case studies

6. Dual primary listing in Hong Kong
- Case studies

7. Subsequent delist from other exchange
- Case studies

8. Secondary listing in Hong Kong

9. Joint policy statement 2013
- Case studies

10. Chapter 19C
- Case studies

對象

- Sponsors and IPO practitioners
- Corporate finance advisers
- Executives, senior management and company secretaries of already listed companies preparing for listing in Hong Kong
- Asset and fund managers
- Investors who are interested in returning China Concepts companies